Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK3 | O43781 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | CLK3 | P49761 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.41 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.41 |
| ▸ | MYLK2 | Q9H1R3 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2992635 | 1.00 | DYRK3 (0.44) | DYRK3EPHX2PIK3CDPIM1CSNK2A2 | |
| SCHEMBL2998969 | 0.98 | DYRK3 (0.44) | DYRK3EPHX2PIK3CDPIM1CSNK2A2 | |
| SCHEMBL2998972 | 0.98 | DYRK3 (0.44) | DYRK3EPHX2PIK3CDPIM1CSNK2A2 | |
| SCHEMBL2992954 | 0.98 | DYRK3 (0.44) | DYRK3EPHX2PIK3CDPIM1CSNK2A2 | |
| SCHEMBL2992956 | 0.98 | DYRK3 (0.44) | DYRK3EPHX2PIK3CDPIM1CSNK2A2 | |
| SCHEMBL3641944 | 0.95 | DYRK3 (0.46) | DYRK3EPHX2PIK3CDPIM1CSNK2A2 | |
| SCHEMBL3641946 | 0.95 | DYRK3 (0.46) | DYRK3EPHX2PIK3CDPIM1CSNK2A2 | |
| SCHEMBL2984386 | 0.91 | DYRK3 (0.46) | DYRK3EPHX2PIK3CDPIM1CSNK2A2 | |
| SCHEMBL2984388 | 0.91 | DYRK3 (0.46) | DYRK3EPHX2PIK3CDPIM1CSNK2A2 | |
| SCHEMBL2988900 | 0.90 | EGFR (0.40) | DYRK3PIK3CDCSNK2A2PIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216801-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-08-26 | — | — | US | claimed |
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-08-13 | — | — | US | claimed |
| EP-1993538-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-11-26 | — | — | EP | claimed |
| WO-2007103758-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | claimed |
| US-20100216801-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-08-26 | — | — | US | disclosed |
| US-20100184774-A1 | METHODS OF TREATMENT | SMITHKLINE BEECHAM CORPORATION | 2010-07-22 | — | — | US | disclosed |
| EP-2164494-A1 | METHODS OF TREATMENT | GlaxoSmithKline LLC (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-08-13 | — | — | US | disclosed |
| WO-2008150837-A1 | METHODS OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| EP-1993538-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1885362-A2 | NOVEL CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2007103758-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2006127458-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216801-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | PIK3CA, BTK, PI4KA | DYRK3 1357/4885EPHX2 4084/4885PIK3CD 4/4885 |
| US-20100184774-A1 | METHODS OF TREATMENT | OPRL1, BRCA1, PKD1 | DYRK3 3748/4885EPHX2 4832/4885PIK3CD 3361/4885 |
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | HIPK3, HIPK1, HIPK4 | DYRK3 1471/4885EPHX2 3147/4885PIK3CD 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.